REFERENCES

1. Senanayake N, Roman GC. Epidemiology of epilepsy in developing countries. Bull World Health Organ 1993; 71(2): 247-58.
2. Scharf D. Neurocysticercosis: two-hundred thirty-eight cases from a California hospital. Arch Neurol 1988; 45:777-80.
3. Suss RA, Maravilla KR, Thompson J. MR imaging of intracranial cysticercosis: comparison with CT and anatomopathologic features. Am J Neurorad 1986; 7:235-42.
4. Garcia HH, Martinez M, Gilman R, et al. Diagnosis of cysticercosis in endemic regions. Lancet 1991; 338:549-51.
5. Sotelo J, Torres B, Rubio-Donnadieu F, et al. Praziquantel in the treatment of neurocysticercosis: long-term follow-up. Neurology 1985; 35:752-5.
6. Cruz M, Cruz I, Horton J. Albendazole versus praziquantel in the treatment of cerebral cysticercosis: clinical evaluation. Trans R Soc Trop Med Hyg 1991; 85:244-7.
7. Takayanagui OM, Jardim E. Therapy for neurocysticercosis comparison between albendazole and praziquantel. Arch neurol 1992; 49:290-4.
8. Sotelo J, Del Brutto OH, Penagos P, et al. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol 1990; 237:69-72.
9. Del Brutto OH, Sotelo J, Roman GC. Therapy for Neurocysticercosis: A Reappraisal. Clin Infect Dis 1993; 17(4): 730-5.
10. Medina MT, Cordova S, Genton P, et al. Prognosis of epilepsy in neurocysticercosis: the effect of anticysticercal treatment. Epilepsia 1991; 32(suppl 1): 110-1.
11. Monteiro L, Almeida-Pinto J, Stocker A, et al. Active neurocysticercosis, parenchymal and extraparenchymal: a study of 38 patients. J Neurol 1993; 241(1):15-21.